Faricimab for High-frequent Aflibercept Treated Neovascular Age-related Macular Degeneration

NCT05941715 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

70

Enrollment

OTHER

Sponsor class

Conditions

Neovascular Age-related Macular Degeneration

Interventions

DRUG: Aflibercept 40 MG/ML
DRUG: Faricimab 120 MG/ML

Sponsor

Medical University of Graz